Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BCTX NASDAQ:CTMX NASDAQ:OPTN NASDAQ:UNCY On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$12.32+5.1%$9.10$6.00▼$190.50$8.38M1.21106,905 shs54,644 shsCTMXCytomX Therapeutics$3.28-3.8%$2.42$0.40▼$3.51$540.92M2.273.36 million shs1.84 million shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AUNCYUnicycive Therapeutics$4.93+2.7%$4.27$3.71▼$11.00$87.06M1.86384,235 shs802,260 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+2.63%-7.86%+44.87%+40.97%-91.32%CTMXCytomX Therapeutics-0.29%+1.19%+71.36%+43.28%+204.46%OPTNOptiNose0.00%0.00%0.00%0.00%-9.03%UNCYUnicycive Therapeutics+5.26%+0.63%+21.83%+3.23%+20.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBCTXBriacell Therap$12.32+5.1%$9.10$6.00▼$190.50$8.38M1.21106,905 shs54,644 shsCTMXCytomX Therapeutics$3.28-3.8%$2.42$0.40▼$3.51$540.92M2.273.36 million shs1.84 million shsOPTNOptiNose$9.60$9.57$4.82▼$17.18$97.22M-0.8863,682 shsN/AUNCYUnicycive Therapeutics$4.93+2.7%$4.27$3.71▼$11.00$87.06M1.86384,235 shs802,260 shsThe Best High-Yield Dividend Stocks for 2025Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBCTXBriacell Therap+2.63%-7.86%+44.87%+40.97%-91.32%CTMXCytomX Therapeutics-0.29%+1.19%+71.36%+43.28%+204.46%OPTNOptiNose0.00%0.00%0.00%0.00%-9.03%UNCYUnicycive Therapeutics+5.26%+0.63%+21.83%+3.23%+20.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBCTXBriacell Therap 2.00Hold$320.002,497.40% UpsideCTMXCytomX Therapeutics 3.00Buy$5.4265.14% UpsideOPTNOptiNose 2.00Hold$9.00-6.25% DownsideUNCYUnicycive Therapeutics 2.75Moderate Buy$57.001,056.19% UpsideCurrent Analyst Ratings BreakdownLatest BCTX, CTMX, UNCY, and OPTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BCTXBriacell TherapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)10/8/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)10/8/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025BCTXBriacell TherapWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)9/27/2025CTMXCytomX TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/27/2025UNCYUnicycive TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/22/2025CTMXCytomX TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.009/22/2025CTMXCytomX TherapeuticsCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$6.009/17/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$3.509/16/2025CTMXCytomX TherapeuticsBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/15/2025UNCYUnicycive TherapeuticsBenchmarkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSpeculative Buy$21.00(Data available from 10/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBCTXBriacell TherapN/AN/AN/AN/A($22.02) per shareN/ACTMXCytomX Therapeutics$141.10M3.83$0.35 per share9.45($0.01) per share-328.00OPTNOptiNose$81.86M1.19N/AN/A($11.56) per share-0.83UNCYUnicycive Therapeutics$680K128.04N/AN/A$0.72 per share6.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBCTXBriacell Therap-$4.79M-$83.18N/AN/AN/AN/A-479.97%-182.26%10/27/2025 (Estimated)CTMXCytomX Therapeutics$31.87M$0.565.86N/AN/A34.04%158.70%36.04%11/6/2025 (Estimated)OPTNOptiNose-$35.48M-$3.00N/AN/AN/A-41.16%N/A-27.42%N/AUNCYUnicycive Therapeutics-$36.73M-$4.12N/AN/AN/AN/A-243.13%-119.46%11/12/2025 (Estimated)Latest BCTX, CTMX, UNCY, and OPTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/12/2025N/AUNCYUnicycive Therapeutics-$0.62N/AN/AN/AN/AN/A11/6/2025Q3 2025CTMXCytomX Therapeutics-$0.04N/AN/AN/A$11.50 millionN/A10/27/2025N/ABCTXBriacell Therap-$12.11N/AN/AN/AN/AN/A8/14/2025Q2 2025UNCYUnicycive Therapeutics-$0.70-$0.52+$0.18-$0.52N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBCTXBriacell TherapN/AN/AN/AN/AN/ACTMXCytomX TherapeuticsN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/AUNCYUnicycive TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBCTXBriacell TherapN/A3.413.41CTMXCytomX TherapeuticsN/A4.204.20OPTNOptiNoseN/A0.790.72UNCYUnicycive TherapeuticsN/A2.182.18Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBCTXBriacell Therap15.42%CTMXCytomX Therapeutics67.77%OPTNOptiNose85.60%UNCYUnicycive Therapeutics40.42%Insider OwnershipCompanyInsider OwnershipBCTXBriacell Therap5.73%CTMXCytomX Therapeutics6.60%OPTNOptiNose2.30%UNCYUnicycive Therapeutics10.71%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBCTXBriacell Therap8680,000639,000No DataCTMXCytomX Therapeutics170164.91 million154.03 millionOptionableOPTNOptiNose19010.13 million9.83 millionNot OptionableUNCYUnicycive Therapeutics917.66 million15.77 millionNot OptionableBCTX, CTMX, UNCY, and OPTN HeadlinesRecent News About These CompaniesUNCY Deadline Today: Rosen Law Firm Urges Unicycive Therapeutics, Inc. (NASDAQ: UNCY) Stockholders with Large Losses to Contact the Firm for Information About Their RightsOctober 14 at 12:20 PM | businesswire.comUNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud LawsuitOctober 14 at 2:55 AM | prnewswire.comUnicycive Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - UNCYOctober 13 at 5:31 PM | prnewswire.comUNCY Investors Have Opportunity to Lead Unicycive Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law FirmOctober 13 at 4:48 PM | prnewswire.comThe Gross Law Firm Reminds Unicycive Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 14, 2025 – UNCYOctober 13 at 4:00 PM | globenewswire.comPortnoy Law Firm Announces Class Action on Behalf of Unicycive Therapeutics, Inc. InvestorsOctober 13 at 3:41 PM | globenewswire.comPomerantz Law Firm Announces the Filing of a Class Action Against Unicycive Therapeutics, Inc. and Certain Officers - UNCYOctober 13 at 2:34 PM | prnewswire.comFINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsOctober 13 at 12:23 PM | businesswire.comUNCY INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Unicycive Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action LawsuitOctober 13 at 12:00 PM | globenewswire.comUNICYCIVE DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Investors in Unicycive to Contact the Firm Before the October 14th Deadline in the Filed Class Action LawsuitOctober 13 at 11:41 AM | globenewswire.comThe Gross Law Firm Notifies Shareholders of Unicycive Therapeutics, Inc.(UNCY) of a Class Action Lawsuit and an Upcoming DeadlineOctober 13 at 9:00 AM | prnewswire.comROSEN, A LEADING AND TOP RANKED LAW FIRM, Encourages Unicycive Therapeutics, Inc. Investors to Secure Counsel Before Important October 14 Deadline in Securities Fraud Lawsuit – UNCYOctober 12, 2025 | globenewswire.comUNCY INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Unicycive TherapeuticsOctober 12, 2025 | globenewswire.comLost Money on Unicycive Therapeutics, Inc. (UNCY)? Contact Levi & Korsinsky Before October 14, 2025 to Join Class ActionOctober 11, 2025 | theglobeandmail.comWall Street Zen Upgrades Unicycive Therapeutics (NASDAQ:UNCY) to "Hold"October 11, 2025 | marketbeat.comSHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UnicyciveOctober 10, 2025 | prnewswire.comHolzer & Holzer, LLC Reminds Investors of Upcoming Lead Plaintiff Deadlines in Shareholder Class Action Lawsuits Against Unicycive Therapeutics (UNCY) and KinderCare Learning Companies, Inc. (KLC)October 10, 2025 | globenewswire.comUNICYCIVE REMINDER: Bragar Eagel & Squire, P.C. Urges Investor to Contact the Firm Before the October 14th DeadlineOctober 10, 2025 | globenewswire.comUNCY LAWSUIT ALERT: Levi & Korsinsky Notifies Unicycive Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming DeadlineOctober 10, 2025 | prnewswire.comROSEN, REGARDED INVESTOR COUNSEL, Encourages Unicycive Therapeutics, Inc. Investors to Secure ...October 10, 2025 | caledonianrecord.comCInvestors in Unicycive Therapeutics, Inc. (UNCY): Protect Your Rights - Contact Levi & Korsinsky Before October 14, 2025October 10, 2025 | theglobeandmail.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBCTX, CTMX, UNCY, and OPTN Company DescriptionsBriacell Therap NASDAQ:BCTX$12.32 +0.60 (+5.12%) Closing price 04:00 PM EasternExtended Trading$12.11 -0.21 (-1.70%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer. The company is also developing Bria-OTS, a platform of personalized off-the-shelf cell-based immunotherapies, which is being evaluated in a Phase 1/2 clinical studies targeting breast cancer with extension to prostate cancer and other cancers. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.CytomX Therapeutics NASDAQ:CTMX$3.28 -0.13 (-3.81%) Closing price 04:00 PM EasternExtended Trading$3.28 +0.01 (+0.15%) As of 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.OptiNose NASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Unicycive Therapeutics NASDAQ:UNCY$4.93 +0.13 (+2.71%) Closing price 04:00 PM EasternExtended Trading$4.93 +0.00 (+0.10%) As of 06:19 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Qualcomm: What Last Friday’s Drop Says About Its Q4 Prospects An AI Play Hiding in Plain Sight: A Look at Johnson Controls Walmart's AI Play: OpenAI Deal Forges a New Path to Profitability AppLovin Drops 14%: Should Investors Worry About SEC Probe? Advanced Micro Devices Eyes $300 as AI Demand Surges From Bulldozers to Big Data: Caterpillar’s Bull Case Gets a Lift Why Analysts Are Upgrading Ratings After Klarna's IPO 3 Healthcare Companies Insiders Are Buying Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
